Clinical trials: Neoplasm Circulating Cells
Lung Cancer (Diagnosis), Circulating Tumor Cell
Liquid Biopsy in Lung Cancer
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
- Trial name
- NCT03479099
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Samsung Medical Center
Pancreatic Cancer, Circulating Tumor Cell
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed…
- Conditions
- Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model
- Trial name
- LIQUIPANC (NCT06391892)
- Testing
- Neoadjuvant chemotherapy instead of upfront surgery, Upfront surgery
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Elisabethinen Hospital
Metastatic Breast Cancer
Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients
Characterization of the driver mutations in an individual metastatic breast cancer patient is critical for many reasons. Effective targeted therapies require identifying genomic alterations in the tumoral tissue.
- Trial name
- MIRROR (NCT02626039)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Carcinoma, Hepatocellular, Neoplasm Circulating Cells
Circulating Tumor Cells for Hepatocellular Carcinoma
To explore the clinical value of circulating tumor cells (CTCs) measurement for Hepatocellular carcinoma (HCC) patients.
- Trial name
- CTCs for HCC (NCT01930383)
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Metastatic Breast Cancer
Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer
A prospective, single-centre, proof-of-concept pilot study in patients with metastatic breast cancers (MBC) (whatever the immunohistochemical subtype) treated at the IUCT-O.
- Trial name
- DP METABREAST (NCT06408038)
- Testing
- For each patient included, the samples described below will be collected:
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Cancer, Immune System or Toxicities Suspected
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
- Trial name
- ALCYTA (NCT05354765)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Circulating Tumor Cells
Cancer DNA Screening Pilot Study (CANDACE)
The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor.
- Trial name
- CANDACE (NCT02808884)
- Testing
- Circulating tumor DNA assay
- Where
- Canada
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Brain Cancer, Breast Cancer
Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer
This study assesses the number of CTCs before and 4-5 weeks after focal stereotactic radiotherapy, in single or fractionated dose, and correlate with the local and distant brain progression-free survival in patients with…
- Trial name
- NCT02941536
- Testing
- Circulating tumor cells evaluation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- AC Camargo Cancer Center
Cervical Cancer, Recurrent Cervical Cancer
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis…
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Trial name
- NCT07673211
- Testing
- Biospecimen collection (peripheral blood and paraffin tumor tissue)
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.
- Trial name
- NCT02418234
- Testing
- mutation detection, ARMS and ddPCR, ctDNA analysis
- Where
- China
- Volunteers
- 314 people
- Sponsor
- First People's Hospital of Hangzhou
Prostate Cancer
Influence of EMT on CTCs and Disease Progression in Prostate Cancer
The presence of circulating tumor cells (CTCs) in the blood of prostate cancer patients has been shown to be an important indicator of metastatic disease and poor prognosis.
- Trial name
- NCT04021394
- Testing
- CellSearch CTC platform, Parsortix CTC platform
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non Small Cell Lung Cancer, Circulating Tumor Cell
Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with…
- Trial name
- NCT05619562
- Testing
- Device for CTC/DTC detection
- Where
- Czechia
- Volunteers
- 166 people
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Non-Clear Cell Renal Cell Carcinoma
Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma
This is a prospective, non-interventional observational cohort study evaluating the clinical utility of patient-specific circulating tumor DNA (ctDNA) monitoring in patients with advanced non-clear cell renal cell carcinoma…
- Trial name
- NCT07776483
- Testing
- Patient-Specific Tumor-Informed ctDNA Monitoring
- Volunteers
- 67 people
- Sponsor
- West China Hospital
Non Small Cell Lung Cancer
A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases.
- Trial name
- LUNGadenosine (NCT05648188)
- Testing
- Sample
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Nice
Women With BRCA1 Germline Deleterious Mutation
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
BRCA1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included. These patients will be followed up during 30 months (2,5 years) with mutated TP53 mutation detection or during 42…
- Trial name
- NCT02608346
- Testing
- Blood sampling
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- Institut Curie
Bladder Cancer, Urothelial Carcinoma
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
- Trial name
- RETAIN-3 (NCT07908979)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fox Chase Cancer Center
Cancer
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric
ASCEND-Gastric is a prospective, multi-omics, observational study aimed at detecting gastric cancer by combined assays for serum protein markers, deep sequencing of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA) mutation…
- Trial name
- ASCEND-Gastric (NCT05224596)
- Testing
- Blood draw and blood-based biomarkers analyses
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Shanghai Zhongshan Hospital
Glioma, Malignant
Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023).
- Trial name
- GliomiR (NCT06203496)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen